Cited by 417RNA Interference and Gene DeliveryDNA and Nucleic Acid ChemistryRNA Research and Splicing

The DOI matches its Crossref record; 241 of the 243 references it cites were found in a registry or an index.

Progress in Antisense Technology

Crooke, Stanley T.·2004·Annual Review of Medicine

DOI 10.1146/annurev.med.55.091902.104408

Open this paper in CoChat — free account

Abstract

Antisense technology exploits oligonucleotide analogs to bind to target RNAs via Watson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradation of the target RNA. Antisense agents can also alter splicing. During the past decade, much has been learned about the basic mechanisms of antisense, the medicinal chemistry, and the pharmacologic, pharmacokinetic, and toxicologic properties of antisense molecules. Antisense technology has proven valuable in gene functionalization and target validation. With one drug marketed, Vitravenetm, and approximately 20 antisense drugs in clinical development, it appears that antisense drugs may prove important in the treatment of a wide range of diseases.

Integrity signals

Registry

Crossref · 10.1146/annurev.med.55.091902.104408

Cites

241 of 241 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
RNAi
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,751
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Predicting DNA duplex stability from the base sequence
Breslauer, K. J., Frank, R., Blöcker, H., & Marky, L. A. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3746 · Cited by 1,837
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Functional genomic analysis of C. elegans chromosome I by systematic RNA interference
Fraser, A. G., Kamath, R. S., Zipperlen, P., Martinez-Campos, M., Sohrmann, M., & Ahringer, J. (2000) · Nature · doi:10.1038/35042517 · Cited by 1,761
Anti-cancer Drug Design
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,352
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Summerton, J. E., & Weller, D. D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,137
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems
Caplen, N. J., Parrish, S., Imani, F., Fire, A. Z., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,042
Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III
Gönczy, P., Echeverri, C. J., Oegema, K., Coulson, A. R., Jones, S. J. M., Copley, R. R., Duperon, J., Oegema, J., Brehm, M., Cassin, E., et al. (2000) · Nature · doi:10.1038/35042526 · Cited by 874
Targeted mRNA degradation by double-stranded RNA in vitroPreprint
Tuschl, T., Zamore, P. D., Lehmann, R., Bartel, D. P., & Sharp, P. A. (1999) · Genes & Development · doi:10.1101/gad.13.24.3191 · Cited by 858
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D. P. C., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 779
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J. W., Lee, S., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 775
Characterization of oligonucleotide transport into living cells.
Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., & Neckers, L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3474 · Cited by 734
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., & ROSENBERG, R. D. (1992) · Nature · doi:10.1038/359067a0 · Cited by 731
CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen
Davis, H. L., Weeranta, R., Waldschmidt, T. J., Tygrett, L. T., Schorr, J., & Krieg, A. Μ. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.2.870 · Cited by 676
Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.
Bennett, C. F., Chiang, M. Y., Chan, H. E. H., Shoemaker, J. E., & Mirabelli, C. K. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09229-6 · Cited by 612
Antisense Research and Applications
Agrawal, S., & Crooke, S. T. (1993) · Medical Entomology and Zoology · Cited by 610
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells
Hartmann, G., & Krieg, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.944 · Cited by 605
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 559
Antisense and Antigene Properties of Peptide Nucleic Acids
Hanvey, J. C., Peffer, N. J., Bisi, J., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) · Science · doi:10.1126/science.1279811 · Cited by 538
Modulation of Anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides
Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F., & Heilig, M. A. (1993) · Science · doi:10.1126/science.8380941 · Cited by 524
Therapeutic Applications Of Oligonucleotides
Crooke, S. T. (1992) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.32.1.329 · Cited by 514
Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.
Chiang, M. Y.-N., Chan, H., Zounes, M. A., Freier, S., Lima, W. F., & Bennett, C. F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55250-9 · Cited by 463
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
Self-citation
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F. I., Stefano, F. D., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.
Walder, R. Y., & Walder, J. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5011 · Cited by 453
Genetic Requirements for Inheritance of RNAi in C. elegans
Grishok, A., Tabara, H., & Mello, C. C. (2000) · Science · doi:10.1126/science.287.5462.2494 · Cited by 449
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
Monia, B. P., Johnston, J. F., Geiger, T. M., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447
Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo
Osen‐Sand, A., Catsicas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G., & Catsicas, S. (1993) · Nature · doi:10.1038/364445a0 · Cited by 442
Uniformly modified 2'-deoxy-2'-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 439
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Domiński, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation
Maher, L. J., Wold, B. J., & Dervan, P. B. (1989) · Science · doi:10.1126/science.2549631 · Cited by 409
Antisense Gene Inhibition by Oligonucleotides Containing C-5 Propyne Pyrimidines
Wagner, R. W., Matteucci, M. D., Lewis, J. G., Gutierrez, A. J., Moulds, C., & Froehler, B. C. (1993) · Science · doi:10.1126/science.7684856 · Cited by 406
Extension of the Life-Span of Human Endothelial Cells by an Interleukin-1αAntisense Oligomer
Maier, J. A. M., Voulalas, P. J., Roeder, D., & Maciag, T. (1990) · Science · doi:10.1126/science.2218499 · Cited by 400
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.
Zamecnik, P. C., Goodchild, J., Taguchi, Y., & Sarin, P. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4143 · Cited by 400
Site specific enzymatic cleavage of RNA
Donis-Keller, H. (1979) · Nucleic Acids Research · doi:10.1093/nar/7.1.179 · Cited by 399
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis
Der, S. D., Yang, Y.-L., Weissmann, C., & Williams, B. R. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3279 · Cited by 389
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
Yacyshyn, B., Bowen-Yacyshyn, M. B., Jewell, L. D., Tami, J. A., Bennett, C. F., Kisner, D. L., & Shanahan, W. R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70418-4 · Cited by 380
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
Messina, J. P., Gilkeson, G. S., & Pisetsky, D. S. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.6.1759 · Cited by 374
Real time detection of DNA⋅RNA hybridization in living cells
Sokol, D. L., Zhang, X., Lu, P., & Gewirtz, A. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11538 · Cited by 374
Estimation of the aqueous solubility I: Application to organic nonelectrolytes
Jain, N., & Yalkowsky, S. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200102)90:2 · Cited by 368
Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice
Cerritelli, S. M., Frolova, E. G., Feng, C., Grinberg, A., Love, P. E., & Crouch, R. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00088-1 · Cited by 358
Ancient Pathways Programmed by Small RNAs
Zamore, P. D. (2002) · Science · doi:10.1126/science.1072457 · Cited by 357
Base pairing involving deoxyinosine: implications for probe design
Martin, F. H., Castro, M. M., Aboul‐ela, F., & Tinoco, I. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.24.8927 · Cited by 342
Ribonucleases : structures and functions
D’Alessio, G., & Riordan, J. F. (1997) · Cited by 336
Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.
Lemaitre, M. M., Bayard, B., & Lebleu, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.648 · Cited by 330
The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.
Burgess, T. L., Fisher, E. F., Ross, S. L., BREADY, J. V., Qian, Y., Bayewitch, L. A., Cohen, A. M., Herrera, C., Hu, S., & Kramer, T. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.4051 · Cited by 320
Combinatorially selected guanosine-quartet structureis a potent inhibitor of human immunodeficiency virus envelope-mediated cellfusion.
Wyatt, J. R., Vickers, T. A., Roberson, J. L., Buckheit, R. W., Klimkait, T., DeBaets, E. L., Davis, P. W., Rayner, B., IMBACH, J. ‐., & Ecker, D. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1356 · Cited by 301
Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5.
Smith, C. C., Aurelian, L., Reddy, M. P., Miller, P. S., & Ts’o, P. O. P. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2787 · Cited by 297
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.
Dean, N. M., McKay, R. A., Condon, T. P., & Bennett, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34023-1 · Cited by 291
Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.
Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A., Sarin, P. S., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7079 · Cited by 291
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
Geary, R. S., Watanabe, T. A., Truong, L., Freier, S., Lesnik, E. A., Sioufi, N. B., Sasmor, H. M., Manoharan, M., & Levin, A. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38831-7 · Cited by 289
In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits
Griffin, L., Tidmarsh, G. F., Bock, L. C., Toole, J. J., & Leung, L. L. K. (1993) · Blood · doi:10.1182/blood.v81.12.3271.3271 · Cited by 285
Activation of human B cells by phosphorothioate oligodeoxynucleotides.
Liang, H., Nishioka, Y., Reich, C. F., Pisetsky, D. S., & Lipsky, P. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118894 · Cited by 284
Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B
Kitajima, I., Shinohara, T., Bilakovics, J. M., Brown, D., Xu, X., & Nerenberg, M. I. (1993) · Science · doi:10.1126/science.8456277 · Cited by 278
Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases
Sproat, B. S., Lamond, A. I., Beijer, B., Neuner, P., & Ryder, U. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.9.3373 · Cited by 271
Antisense Drug Technology
(2010) · CRC Press eBooks · doi:10.1201/9781420002546 · Cited by 270
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
Zhang, H., Cook, J., Nickel, J., Yu, R. Z., Stecker, K., Myers, K. J., & Dean, N. M. (2000) · Nature Biotechnology · doi:10.1038/78475 · Cited by 268
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands, H., Gorey‐Feret, L. J., Cocuzza, A. J., Hobbs, F. W., Chidester, D. R., & Trainor, G. L. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10208-3 · Cited by 267
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum, P. A., Sasmor, H. M., Dellinger, D., Truong, L., Cummins, L. M., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39459-0 · Cited by 265
Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression.
Higgins-Sochaski, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K. A., McComas, W. A., Sarmiento, U. M., Rosen, C. A., & Narayanan, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.9901 · Cited by 261
Antisense oligonucleotide strategies in neuropharmacology
Wahlestedt, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90107-4 · Cited by 261
DNA antisense therapy for asthma in an animal model
Nyce, J. W., & Metzger, W. J. (1997) · Nature · doi:10.1038/385721a0 · Cited by 258
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.
Wang, S., Lee, R. J., Cauchon, G., Gorenstein, D. G., & Low, P. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3318 · Cited by 257
α-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media
Bacon, T. A., Morvan, F., Rayner, B., Imbach, J., & Wickstrom, E. (1988) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(88)90065-6 · Cited by 255
Effects of phosphorothioate capping on antivense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection
Hoke, G. D., Draper, K. G., Freier, S. M., Gonzalez, C., Brown‐Driver, V., Zounes, M. C., & Ecker, D. J. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5743 · Cited by 248
Inhibition of protein kinase B/Akt
Hill, M. M. C., & Hemmings, B. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00193-6 · Cited by 247
The use of single-stranded DNA and RNase H to promote quantitative ‘hybrid arrest of translation’ of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
Minshull, J., & Hunt, T. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.16.6433 · Cited by 244
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
Dean, N. M., & McKay, R. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11762 · Cited by 242
Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey
Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., & Agrawal, S. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.201 · Cited by 238
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides
Cazenave, C., Stein, C. A., Loreau, N., Thuong, N. T., Neckers, L., Subasinghe, C., Hélène, C., Cohen, J. S., & Toulmé, J. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.11.4255 · Cited by 238
Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide
Martin, P. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780219 · Cited by 235
dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference
Caplen, N. J., Fleenor, J., Fire, A. Z., & Morgan, R. A. (2000) · Gene · doi:10.1016/s0378-1119(00)00224-9 · Cited by 234
Oligodeoxynucleotide stability in subcellular extracts and culture media
Wickstrom, E. (1986) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(86)90021-7 · Cited by 234
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression
Ghosh, M. K., & Cohen, J. S. (1992) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60574-7 · Cited by 233
Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology.
Gao, W., Han, F. S., Storm, C., Egan, W., & Cheng, Y.-T. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08861-3 · Cited by 232
Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid
Campbell, J. M., Bacon, T. A., & Wickstrom, E. (1990) · Journal of Biochemical and Biophysical Methods · doi:10.1016/0165-022x(90)90084-p · Cited by 230
Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B., Cummins, L. L., Greig, M. J., Guinosso, C. J., Kornbrust, D. J., Manoharan, M., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12951-0 · Cited by 227
Implication of RNA structure on antisense oligonucleotide hybridization kinetics
Lima, W. F., Monia, B. P., Ecker, D. J., & Freier, S. M. (1992) · Biochemistry · doi:10.1021/bi00163a013 · Cited by 226
Burger's Medicinal Chemistry and Drug Discovery
Shader, R. I. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00018 · Cited by 226
Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M. K., Auletta, C. S., Levin, A. A., & Kornbrust, D. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
Azad, R. F., Brown‐Driver, V., Tanaka, K., Crooke, R. M., & Anderson, K. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1945 · Cited by 203
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide
Majumdar, C., Stein, C. A., Cohen, J. S., Broder, S. E., & Wilson, S. H. (1989) · Biochemistry · doi:10.1021/bi00429a060 · Cited by 187
Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes
Crooke, S. T., Lemonidis, K. M., Neilson, L. I., Griffey, R. H., Lesnik, E. A., & Monia, B. P. (1995) · Biochemical Journal · doi:10.1042/bj3120599 · Cited by 186
Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
Ho, S. P., Bao, Y., Lesher, T., Malhotra, R., Ma, L. Y., Fluharty, S. J., & Sakai, R. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0198-59 · Cited by 186
RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds
Furdon, P. J., Domiński, Z., & Kole, R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.22.9193 · Cited by 178
Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-
Monia, B. P., Johnston, J. F., Sasmor, H. M., & Cummins, L. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.24.14533 · Cited by 177
Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean, N. S., McKay, R. A., Miraglia, L. J., Howard, R., Cooper, S. R., Giddings, J., Nicklin, P. L., Meister, L., Ziel, R., Geiger, T. M., et al. (1996) · PubMed · Cited by 175
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skórski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C. A., Iversen, P. L., Iozzo, R. V., Zon, G., & Calabretta, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4504 · Cited by 172
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
Nemunaitis, J. J., Holmlund, J., Kraynak, M. A., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R. S., Dorr, A., Hoff, D. V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3586 · Cited by 172
Tricyclic 2'-Deoxycytidine Analogs: Syntheses and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA
Lin, K., Jones, R. J., & Matteucci, M. D. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00118a026 · Cited by 164
Properties of Cloned and Expressed Human RNase H1
Wu, H., Lima, W. F., & Crooke, S. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28270 · Cited by 159
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice
Henry, S. P., Stecker, K., Brooks, D., Monteith, D., Conklin, B., & Bennett, C. F. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35315-7 · Cited by 152
Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler, M., Stecker, K., & Bennett, C. F. (1997) · PubMed · Cited by 151
Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide
McManaway, M. E., Alnasser, A., Shiramizu, B. T., Goldschmidts, W., Bhatia, K. G., MAGRATH, I. T., Neckers, L., Loke, S. L., Redner, R. L., & Huber, B. E. (1990) · The Lancet · doi:10.1016/0140-6736(90)90934-w · Cited by 150
Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial
Bayever, E., Iversen, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger, A., Zon, G., et al. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.383 · Cited by 149
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., & Sikic, B. I. (1999) · PubMed · Cited by 148
Prothymosin alpha antisense oligomers inhibit myeloma cell division.
Sburlati, A. R., Manrow, R. E., & Berger, S. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.1.253 · Cited by 142
Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length
Haeuptle, M. T., Frank, R. W., & Dobberstein, B. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.3.1427 · Cited by 141
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
Graham, M. J., Crooke, S. T., Monteith, D., Cooper, S. R., Lemonidis, K. M., Stecker, K., Martin, M. J., & Crooke, R. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37605-0 · Cited by 140
A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
Nesterova, M., & Cho‐Chung, Y. S. (1995) · Nature Medicine · doi:10.1038/nm0695-528 · Cited by 138
Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.
Kulka, M., Smith, C. C., Aurelian, L., Fishelevich, R., Meade, K. S., Miller, P. S., & Ts’o, P. O. P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.6868 · Cited by 137
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J. M., Van, J., Cai, H., Diasio, R. B., Habuš, I., Jiang, Z., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00160-2 · Cited by 136
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures
Giles, R. V., & TIDD, D. M. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.4.763 · Cited by 135
Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide
Clercq, E. D., Eckstein, F., & Merigan, T. C. (1969) · Science · doi:10.1126/science.165.3898.1137 · Cited by 135
Crystal structure of Escherichia coli RNase HI in complex with Mg2+ at 2.8 Å resolution: Proof for a single Mg2+‐binding site
Katayanagi, K., Okumura, M., & Morikawa, K. (1993) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340170402 · Cited by 135
Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302)
Glover, J. M., Leeds, J. M., Mant, T., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., & Shanahan, W. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36939-3 · Cited by 135
Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy
Rappaport, J., Hanss, B. G., Kopp, J. B., Copeland, T. D., Bruggeman, L. A., Coffman, T. M., & Klotman, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.205 · Cited by 132
Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent
Zerial, A., Thuong, N. T., & Hélène, C. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.23.9909 · Cited by 130
Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element
Vickers, T. A., Baker, B. F., Cook, P. D., Zounes, M. C., Buckheit, R. W., Germany, J., & Ecker, D. J. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.12.3359 · Cited by 130
Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*
Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90071-3 · Cited by 129
Oligonucleotide Sequences Required for Natural Killer Cell Activation
Kuramoto, E., Yano, O., Kimura, Y., Baba, M., Makino, T., Yamamoto, S., Yamamoto, T., Kataoka, T., & Tokunaga, T. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02734.x · Cited by 128
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. M., & Agrawal, S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00010-w · Cited by 125
Pyranosyl‐RNA (‘p‐RNA’): Base‐pairing selectivity and potential to replicate. Preliminary communication
Pitsch, S., Krishnamurthy, R., Bolli, M., Wendeborn, S., Holzner, A., Minton, M., Lesueur, C., Schlönvogt, I., Jaun, B., & Eschenmoser, A. (1995) · Helvetica Chimica Acta · doi:10.1002/hlca.19950780702 · Cited by 123
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide
Henry, S. P., Novotny, W. F., LEEDS, J., Auletta, C. S., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.503 · Cited by 122
α-DNA VI: comparative study of α- and β-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition
Gagnor, C., Bertrand, J.-R., Thenet, S., Lemaitre, M. M., Morvan, F., Rayner, B., Malvy, C., Lebleu, B., Imbach, J., & Paoletti, C. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.24.10419 · Cited by 121
Carbohydrate Modifications in Antisense Research
Sanghvi, Y. S., & Cook, P. D. (1994) · ACS symposium series · doi:10.1021/bk-1994-0580 · Cited by 120
In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
Crooke, R. M. (1991) · PubMed · Cited by 120
Progress toward oligonucleotide therapeutics: pharmacodynamic properties
Crooke, S. T. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.7682523 · Cited by 119
Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase Complex
Sheehan, J. P., & Lan, H.-C. (1998) · Blood · doi:10.1182/blood.v92.5.1617 · Cited by 118
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys
Henry, S. P., Bolte, H. F., Auletta, C. S., & Kornbrust, D. J. (1997) · Toxicology · doi:10.1016/s0300-483x(97)03661-5 · Cited by 118
Binding Affinity and Specificity of Escherichia coli RNase H1: Impact on the Kinetics of Catalysis of Antisense Oligonucleotide−RNA Hybrids
Lima, W. F., & Crooke, S. T. (1997) · Biochemistry · doi:10.1021/bi962230p · Cited by 117
Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate
Kanaya, S., Katsuda-Nakai, C., & Ikehara, M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99002-2 · Cited by 116
Suppression of Neointimal Smooth Muscle Cell Accumulation in Vivo by Antisense cdc2 and cdk2 Oligonucleotides in Rat Carotid Artery
Abe, J., Zhou, W. J., Taguchi, J., Takuwa, N., Miki, K., Okazaki, H., Kurokawa, K., Kumada, M., & Takuwa, Y. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1003 · Cited by 115
N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action.
Burch, R. M., Weitzberg, M., Blok, N., Muhlhauser, R. O., Martin, D., Farmer, S. G., Bator, J. M., Connor, J. R., Green, M., & Ko, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.355 · Cited by 115
The Dopamine Transporter and Cocaine Medication Development: Drug Self-Administration in Nonhuman Primates
Howell, L. L., & Wilcox, K. M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29344-7 · Cited by 115
Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity.
Eder, P. S., & Walder, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38142-0 · Cited by 114
5-Heteroaryl-2'-deoxyuridine Analogs. Synthesis and Incorporation into High-Affinity Oligonucleotides
Gutierrez, A. J., Terhorst, T. J., Matteucci, M. D., & Froehler, B. C. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00092a003 · Cited by 112
Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.
Cossum, P. A., Truong, L., Owens, S. R., Markham, P. M., Shea, J. P., & Crooke, S. T. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38714-8 · Cited by 110
Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin
Srinivasan, S. K., Tewary, H. K., & Iversen, P. L. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.131 · Cited by 109
In Vivo Toxicological Effects of rel A Antisense Phosphorothioates in CD-1 Mice
Sarmiento, U. M., Perez, J. R., BECKER, J. M., & Narayanan, R. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.99 · Cited by 109
Antisense Research and Application
Crooke, S. T. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6 · Cited by 109
Detection of Ribonuclease H-Generated mRNA Fragments in Human Leukemia Cells Following Reversible Membrane Permeabilization in the Presence of Antisense Oligodeoxynucleotides
Giles, R. V., Spiller, D. G., & TIDD, D. M. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.23 · Cited by 108
In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.
Crooke, R. M., Graham, M. J., Cooke, M. E., & Crooke, S. T. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12072-7 · Cited by 107
Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues
Lin, P. K. T., & Brown, D. M. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.24.10373 · Cited by 101
Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides
Hall, J., Hüsken, D., Pieles, U., Moser, H. E., & Häner, R. (1994) · Chemistry & Biology · doi:10.1016/1074-5521(94)90008-6 · Cited by 99
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.
Sands, H., Gorey‐Feret, L. J., HO, S. P., Bao, Y., Cocuzza, A. J., Chidester, D. R., & Hobbs, F. W. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08583-9 · Cited by 99
In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats
Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habuš, I., Jiang, Z., Iyer, R. P., Dong, Y. J., & Agrawal, S. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00159-w · Cited by 97
Functional group substitutions as probes of hydrogen bonding between GA mismatches in RNA internal loops
SantaLucia, J., Kierzek, R., & Turner, D. H. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00011a039 · Cited by 96
In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
Iversen, P. L. (1991) · PubMed · Cited by 95
Pseudo—Half-Knot Formation with RNA
Ecker, D. J., Vickers, T. A., Bruice, T. W., Freier, S., Jenison, R. D., Manoharan, M., & Zounes, M. C. (1992) · Science · doi:10.1126/science.1502560 · Cited by 94
In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts
Cowsert, L. M., Fox, M., Zon, G., & Mirabelli, C. K. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.171 · Cited by 94
Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 Mice
Henry, S. P., TAYLOR, J., MIDGLEY, L., Levin, A. A., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.473 · Cited by 94
In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
Zhou, L.-W., Zhang, S., Qin, Z., & Weiss, B. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38956-1 · Cited by 92
Oligodeoxynucleotides Enhance Lipopolysaccharide-Stimulated Synthesis of Tumor Necrosis Factor: Dependence on Phosphorothioate Modification and Reversal by Heparin
Hartmann, G., Krug, A., Waller-Fontaine, K., & Endres, S. (1996) · Molecular Medicine · doi:10.1007/bf03401902 · Cited by 88
Biologic and therapeutic significance of MYB expression in human melanoma.
Hijiya, N., Zhang, J., Ratajczak, M. Z., Kant, J. A., DeRiel, K., Herlyn, M., Zon, G., & Gewirtz, A. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4499 · Cited by 84
Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.
Stein, C. A., Neckers, L. M., Nair, B. C., Mumbauer, S. W., Hoke, G., & Pal, R. (1991) · PubMed · Cited by 83
A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures
Matveeva, O. V. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.5010 · Cited by 82
A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts
Crooke, S. T., Grillone, L. R., Tendolkar, A. V., Garrett, A., Fratkin, M. J., Leeds, J. M., & Barr, W. H. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.189 · Cited by 80
Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice
Temsamani, J., Tang, J. Y., Padmapriya, A. A., Kubert, M., & Agrawal, S. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.277 · Cited by 75
In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
Mirabelli, C. K., Cf, B., Anderson, K., & St, C. (1991) · PubMed · Cited by 75
Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA
Weiss, B., Zhou, L.-W., Zhang, S. P., & Qin, Z. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90426-g · Cited by 74
Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines
Sanghvi, Y. S., Hoke, G. D., Freier, S. M., Zounes, M. C., Gonzalez, C., Cummins, L. L., Sasmor, H. M., & Cook, P. D. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3197 · Cited by 73
Number and distribution of methyiphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates
Quartin, R. S., Brakel, C. L., & Wetmur, G. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.18.7253 · Cited by 71
Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.
Burch, R. M., & Mahan, L. C. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115421 · Cited by 71
Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII
Frank, P. H., Braunshofer-Reiter, C., Wintersberger, U., Grimm, R., & Büsen, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12872 · Cited by 68
Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1
Lima, W. F., & Crooke, S. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27513 · Cited by 67
New synthetic routes to synthons suitable for 2′-O-allyloligoribonucleotide assembly
Sproat, B. S., Iribarre, A. M., Garcı́a, R. G., & Beijer, B. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.4.733 · Cited by 67
Basic Principles of Antisense Therapeutics
Crooke, S. T. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6_1 · Cited by 66
α-DNA IX: parallel annealing of α-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription
Gagnor, C., Rayner, B., Léonetti, J., Imbach, J., & Leblcu, B. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.13.5107 · Cited by 66
Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus
Pisetsky, D. S., & Reich, C. F. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00780-2 · Cited by 65
Tritium labeling of antisense oligonucleotides by exchange with tritiated water
Graham, M. J., Freier, S., Crooke, R. M., Ecker, D. J., Maslova, R. N., & Lesnik, E. A. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.16.3737 · Cited by 63
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
Henry, S. P., Monteith, D., & Levin, A. A. (1997) · PubMed · Cited by 62
Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translationin vitro
Crum, C., Johnson, J. D., Nelson, A., & Roth, D. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.10.4569 · Cited by 61
Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice
Templin, M. V., Levin, A. A., Graham, M. J., Åberg, P. M., AXELSSON, B. I., Butler, M., Geary, R. S., & Bennett, C. F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.359 · Cited by 60
In Vivo Modulation of N- myc Expression by Continuous Perfusion with an Antisense Oligonucleotide
Whitesell, L. J., ROSOLEN, A., & NECKERS, L. M. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.343 · Cited by 58
A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor
Ambühl, P., Gyurko, R., & Phillips, M. I. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00092-p · Cited by 57
Molecular Cloning and Expression of cDNA for Human RNase H
Wu, H., Lima, W. F., & Crooke, S. T. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.53 · Cited by 57
The Induction of Interferon by Natural and Synthetic Polynucleotides
Colby, C. (1971) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60324-4 · Cited by 55
Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line.
Rosolen, A., Whitesell, L. J., Ikegaki, N., Kennett, R. H., & Neckers, L. M. (1990) · PubMed · Cited by 55
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC
Lynch, T. J., Raju, R., Lind, M., Riviere, A., Gatzemeier, U., Dorr, A., Holmlund, J., Yuen, A. R., & Sikic, B. I. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91766-1 · Cited by 54
Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression
Barton, C. M., & Lemoine, N. R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.88 · Cited by 52
The Influence of Antisense Oligonucleotide-induced RNA Structure on Escherichia coli RNase H1 Activity
Lima, W. F., Mohan, V., & Crooke, S. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.18191 · Cited by 52
Absolute Bioavailability of 2′-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats
Geary, R. S., Khatsenko, O. G., Bunker, K., Crooke, R. M., Moore, M., Burckin, T., Truong, L., Sasmor, H. M., & Levin, A. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38832-9 · Cited by 49
Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.
Zhang, S. P., Zhou, L.-W., & Weiss, B. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24032-0 · Cited by 48
Toxicity of Antisense Oligonucleotides
Levin, A. A., Henry, S. P., Monteith, D., & Templin, M. V. (2001) · CRC Press eBooks · doi:10.1201/9781420002546.ch9 · Cited by 48
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats
Zhang, R., Lu, Z., Zhang, X., Zhao, H., Diasio, R. B., Liu, T., Jiang, Z., & Agrawal, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.836 · Cited by 47
Toxicity of Oligodeoxynucleotide Therapeutic Agents
Levin, A. A., Monteith, D., Leeds, J. M., Nicklin, P. L., Geary, R. S., Butler, M., Templin, M. V., & Henry, S. P. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6_5 · Cited by 46
Interaction of Oligodeoxynucleotides with Mammalian Cells
HAWLEY, P., & Gıbson, I. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.185 · Cited by 46
Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified at Terminal Linkages in Mice
MIYAO, T., Takakura, Y., Akiyama, T., Yoneda, F., Sezaki, H., & Hashida, M. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.115 · Cited by 44
Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor.
Zheng, H., Sahai, B. M., Kilgannon, P., Fotedar, A., & Green, D. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3758 · Cited by 43
Synthesis and hybridization of dodecadeoxyribonucleotides containing a fluorescent pyridopyrimidine deoxynucleoside
Inoue, H., Imura, A., & Ohtsuka, E. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.19.7119 · Cited by 43
Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
Henry, S. P., Grillone, L. R., Orr, J. L., Bruner, R. H., & Kornbrust, D. J. (1997) · Toxicology · doi:10.1016/s0300-483x(96)03532-9 · Cited by 42
Control of Gene Expression by Oligodeoxynucleotides Covalently Linked to Intercalating Agents and Nucleic Acid-cleaving Reagents
Hélène, C., & Toulmé, J. (1989) · doi:10.1007/978-1-349-10869-5_8 · Cited by 42
Non-ionic Antisense Oligonucleotides
Miller, P. S. (1989) · doi:10.1007/978-1-349-10869-5_5 · Cited by 41
Therapeutic modulation of cytokines.
Henderson, B. E. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.6.519 · Cited by 41
Toxicological properties of several novel oligonucleotide analogs in mice.
Henry, S. P., Zuckerman, J., Rojko, J. L., Hall, W. C., Harman, R. J., Kitchen, D., & Crooke, S. T. (1997) · PubMed · Cited by 39
Therapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0892-882 · Cited by 39
Modulation of eucaryotic initiation factor-4E binding to 5'-capped oligoribonucleotides by modified anti-sense oligonucleotides.
Baker, B. F., Miraglia, L. J., & Hagedorn, C. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49937-7 · Cited by 37
Oligonucleotide Pharmacotherapy: An Antigene Strategy
Nagel, K. M., Holstad, S. G., & Isenberg, K. E. (1993) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1993.tb02723.x · Cited by 37
DETERMINATION OF BINDING CONSTANTS OF SERUM ALBUMIN FOR PENICILLIN
Joos, R. W., & Hall, W. H. (1969) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)28211-8 · Cited by 37
Microinjected oligonucleotides complementary to the alpha-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes.
Saxena, S. K., & Ackerman, E. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39762-5 · Cited by 36
Use of Cationic Lipids to Enhance the Biological Activity of Antisense Oligonucleotides
Bennett, C. F., Chiang, M.-Y., Chan, H., & Grimm, S. (1993) · Journal of Liposome Research · doi:10.3109/08982109309147445 · Cited by 36
Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System
Takakura, Y., Mahato, R. I., YOSHIDA, M., Kanamaru, T., & Hashida, M. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.177 · Cited by 36
Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Modulate CYP2B1 ExpressionIn Vivo
Desjardins, J. P., Mata, J. E., Brown, T., Graham, D., Zon, G., & Iversen, P. L. (1995) · Journal of drug targeting · doi:10.3109/10611869509015917 · Cited by 35
Preclinical Evaluation of the Effects of a Novel Antisense Compound Targeting C-rafKinase in Mice and Monkeys
Monteith, D. K. B. (1998) · Toxicological Sciences · doi:10.1006/toxs.1998.2527 · Cited by 35
D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
Qin, Z., Zhou, L.-W., Zhang, S., Wang, Y., & Weiss, B. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10528-2 · Cited by 35

Research works printed but not linked: 39

Crouch RJ, 1985, Nucleases, 211
Morvan F, 1991, Anticancer Drug Des., 6, 521
Mirabelli CK, 1991, Anti-Cancer Drug Design, 6, 647
42. Cohen JS. 1993. Phosphorothioate oligodeoxynucleotides. See Ref.42a, pp.205–22
Crooke ST, 1996, J. Pharmacol. Exp. Ther., 277, 923
Joos RW, 1969, J. Pharmacol. Exp. Ther., 166, 113
Crooke RM, 1995, J. Pharmacol. Exp. Ther., 275, 462
Gao W-Y, 1992, Mol. Pharmacol., 41, 223
Stein CA, 1991, J. Acquired Immune Deficiency Syndromes, 4, 686
Cossum PA, 1993, J. Pharmacol. Exp. Ther., 267, 1181
Crooke ST, 1993, Curr. Opin. Invest. Drugs, 2, 1045
Sands H, 1995, Mol. Pharmacol., 47, 636
Crooke RM, 1991, Anti-Cancer Drug Design, 6, 609
67. Crooke RM. 1993. in vitro and in vivo toxicology of first generation analogs. See Ref.42a, pp.471–92
Bennett CF, 1992, Mol. Pharmacol., 41, 1023
Iversen P, 1992, Anticancer Drug Des., 6, 531
Cossum PA, 1994, J. Pharmacol. Exp. Ther., 269, 89
10.1038/clpt.1994.189 · DOI
Butler M, 1997, Lab. Invest., 77, 379
Sands H, 1994, Mol. Pharmacol., 45, 932
Graham MJ, 1998, J. Pharmacol. Exp. Ther., 286, 447
95. Mirabelli CK, Crooke ST. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
103. Crooke ST, Mirabelli CK. 1993. Antisense oligonucleotides in the context of modern molecular drug discovery and development. See Ref.42a, pp.7–35
Zhang S-P, 1994, J. Pharmacol. Exp. Ther., 271, 1462
Dean N, 1996, Cancer Res., 56, 3499
Maksymowych W, 1999, Arthritis Rheumatol., 42, S170
O'Dwyer PJ, 1999, Clin. Cancer Res., 5, 3977
Henry SP, 1997, J. Pharmacol. Exp. Ther., 281, 810
Cornish KG, 1993, Pharmacol.Comm., 3, 239
Henry SP, 1997, Anti-Cancer Drug Des., 12, 395
Wallace TL, 1996, J. Pharmacol. Exp. Ther., 278, 1306
Henry S, 1994, Pharm. Res., 11, S-353/S1-S490
Lemonidis-Farrar K, 2000, Toxicologist, 42, 120
Yuen AR, 1999, Clin. Cancer Res., 5, 3357
164. Crooke ST. 2001. Basic principles. See Ref.46a, pp.1–28
Zellweger T, 2001, J. Pharmacol. Exp. Ther., 298, 1
Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 898
Geary RS, 2001, J. Pharmacol. Exp. Ther., 296, 890
Henry SP, 2000, J. Pharmacol. Exp. Ther., 292, 468

Sorted by citations

Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 909
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
“Currently, over 20 antisense drugs are in various stages of clinical testing [12].”
Background
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
“ASOs are synthetic oligonucleotides modified with a 20-O-(2-methoxy) ethyl modification and phosphorothioate bond to enhance potency, stability, and cell permeability.(49) They are taken up preferentially in liver, adipose tissue, and the kidney, although not in other key tissues such as muscle, brain, or pancreatic b…”
Background
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
“Oligonucleotide-mediated therapies Gene-specific therapy can be mediated by oligonucleotides or oligonucleotide-like compounds, some of which have been shown to have clinical effectiveness in other application”
Background

See all 417

Authors: Crooke, S. T.
Affiliations: Ionis Pharmaceuticals (United States) (US)
Corresponding author: Crooke, Stanley T.
ORCID: Crooke, Stanley T.
Venue: Annual Review of Medicine
Publisher: Annual Reviews
Published: 2004-02-01
Volume: 55
Issue: 1
Pages: 61-95
ISSN: 0066-4219 (ISSN-L)
1545-326X
DOI: 10.1146/annurev.med.55.091902.104408
OpenAlex: W2138668121
Cited by: 417
References: 243
Citations by year: 2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 15 · 2016: 12 · 2015: 14 · 2014: 16 · 2013: 24 · 2012: 32
FWCI: 3.07
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: antisense technology, oligonucleotide analogues, RNA hybridization, RNA degradation, RNA splicing, antisense drug development, pharmacokinetics, toxicity, target validation
MeSH terms: Animals, Humans, Oligonucleotides, Antisense, Biomedical Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress in Antisense Technology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks